Coming soon to the Nasdaq: Biogen's hemophilia spinoff

The biggest life sciences company based in Massachusetts will soon spawn another publicly traded biotech with a similar ticker symbol. Cambridge-based Biogen (Nasdaq: BIIB) announced in May that it planned to spin off its hemophilia business, and the move was formally approved by the company’s board of directors on Dec. 20. The new firm, named Bioverativ, will start with around 400 employees and will be led by John Cox, who pre viously served as Biogen’s executive vice president of pharmaceutical…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news